Neural Tube Defect Screening: Nursing Guide
Neural tube defect screening uses second-trimester maternal serum alpha-fetoprotein (MSAFP), often as part of a quadruple or integrated panel, to estimate fetal open NTD risk — not to diagnose spina bifida or anencephaly at the bedside. Nurses verify gestational dating, collect and label serum correctly, support patients after screen-positive multiples of the median (MoM), and coordinate obstetric follow-up ultrasound without false reassurance from a screen-negative result.
Contents
Quick Facts
Key Takeaway
MSAFP is a screening step — elevated MoM means obstetric teams should review dating, offer targeted ultrasound, and discuss next testing; it never replaces imaging or specialist counseling, and a normal screen.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Gold-top serum gel (preferred) or red-top
Serum separator or plain serum per laboratory maternal screening protocol
Maternal serum (venous blood)
Typically ≥0.5–0.6 mL serum — follow institutional minimum volume
Second trimester maternal screening window per laboratory protocol (commonly approximately 15–20 weeks gestation — confirm local obstetric and laboratory guidance)
No special preparation is usually required
Refrigerated serum commonly acceptable per laboratory; avoid hemolysis. Follow local transport and stability policy.
Often 3–7 days for send-out maternal screening — stat timing not specified in reviewed references
Maternal serum screening / prenatal chemistry send-out
What is Neural Tube Defect Screening?
Neural Tube Defect Screening refers to prenatal laboratory screening — most often maternal serum alpha-fetoprotein (MSAFP) reported as a multiple of the median (MoM) — used to estimate risk for open neural tube defects such as spina bifida and anencephaly. It may be ordered alone or as part of broader second-trimester panels (for example quadruple screening). Results are screening estimates, not fetal diagnoses.
Overview
Antepartum nurses and clinic staff support NTD screening by confirming the order is a maternal serum screen (not adult tumor marker alpha-fetoprotein), verifying gestational age, obtaining serum at the correct window, and preparing patients that abnormal results lead to ultrasound and counseling — not immediate diagnosis. AFP is measured during pregnancy as part of screening such as the quadruple screen.
Major obstetric guidance supports offering prenatal screening for aneuploidy and neural tube defects. MSAFP does not replace detailed fetal anatomy imaging. Non-invasive prenatal testing (NIPT) addresses different aneuploidy questions and is not a substitute for second-trimester MSAFP pathways where those are used. Periconceptional folic acid supplementation reduces NTD risk but does not remove the need for appropriate screening and ultrasound follow-up per public health guidance.
Before venipuncture, confirm gestational dating source, fetal number when known, and that the requisition matches maternal screening. After results, classify screen-positive MoM per laboratory report, notify obstetric teams, schedule or confirm targeted ultrasound, and teach that screening estimates risk — evaluate outcomes when imaging and counseling are completed.
Prenatal Screen-Positive Counseling Safety
Neural tube defect (NTD) screening estimates fetal risk — it does not diagnose spina bifida or anencephaly at the bedside. Nurses prevent harm by verifying gestational dating before collection, avoiding definitive fetal diagnosis language, and ensuring screen-positive results reach obstetric teams for targeted ultrasound and any indicated diagnostic testing.
- Telling a patient a screen-positive maternal serum AFP (MSAFP) result confirms an open neural tube defect before ultrasound or diagnostic testing
- Drawing MSAFP with uncertain gestational age or outdated dating source
- Screen-positive MoM reported without documented obstetric follow-up or anatomy imaging plan
- Reassuring a patient that a screen-negative result guarantees a healthy fetus
Document: gestational age source, specimen timing, MoM or screen classification, patient teaching on screening limits, obstetric notification, and scheduled follow-up imaging or genetics visits.
What NTD Screening Can and Cannot Tell You
This test can help identify:
- Increased population-level risk for open neural tube defects when maternal serum AFP is reported as elevated MoM in the appropriate gestational window
- Need for detailed fetal anatomy ultrasound and obstetric or genetics counseling when screen-positive
- Possible incorrect dating, multiple gestation, or other conditions that can affect AFP interpretation
- Whether additional prenatal testing (for example amniotic fluid studies) may be offered per specialist protocol
This test cannot:
- Diagnose spina bifida, anencephaly, or encephalocele by itself
- Rule out all neural tube defects — closed defects and some anomalies may not raise MSAFP
- Replace targeted ultrasound or diagnostic studies when those are indicated
- Provide certainty about long-term neurologic function or need for surgery before specialist assessment
Gestational Dating and MSAFP Specimen Checks
Verify
Clarify before proceeding when:
- Gestational age is outside the laboratory screening window or conflicts between LMP and ultrasound
- Order appears to be tumor marker AFP on a pregnant patient without obstetric pathway clarification
- Specimen label, tube type, or patient identity does not match
- Patient had fetal demise or reduction since last dating — MSAFP may be misleading
- Screen-positive result is already known but no anatomy ultrasound or obstetric follow-up is documented
- Patient believes the blood test will definitively show whether the baby has spina bifida
- Recent abdominal wall defect or omphalocele is suspected — may affect AFP interpretation
MoM Reporting and Second-Trimester Screening Window
Maternal NTD screening typically uses second-trimester maternal serum AFP reported as a multiple of the median (MoM) adjusted for gestational age, maternal weight, race/ethnicity, and diabetes status per laboratory protocol. Screen-positive cutoffs vary by institution and whether AFP is a single marker or part of a panel (for example quadruple screen).
| Reporting element | Clinical meaning for nurses | Action |
|---|---|---|
| MoM near 1.0 | Near expected median for gestational age on that assay | Continue routine prenatal care; screening limits still apply |
| Elevated MoM (screen-positive) | Increased risk for open NTD and other AFP-related conditions per laboratory interpretation | Notify obstetric team; coordinate targeted ultrasound and counseling — do not diagnose at bedside |
| Low MoM on broader panel | May relate to other aneuploidy screening pathways when part of quad/integrated screen | Follow obstetric genetics protocol — outside NTD-only interpretation |
| Wrong gestational age | Can falsely raise or lower MoM | Clarify dating before patient leaves; repeat only per prescriber and laboratory guidance |
Reference ranges, MoM cutoffs, and critical values may vary by laboratory, institution, analyzer, maternal weight, diabetes status, and clinical context. Always interpret results using the reporting laboratory’s reference materials and local escalation policy.
Integrating MSAFP With Ultrasound and Dating
Pair MSAFP MoM with reliable gestational dating, fetal number, and transvaginal ultrasound or detailed anatomy imaging when screen-positive. AFP is used in prenatal screening such as the quadruple screen; abnormal levels require specialist interpretation — not bedside diagnosis.
| Clinical pattern | May suggest | Nursing focus |
|---|---|---|
| Screen-positive MoM + normal detailed anatomy ultrasound | False-positive screen or alternate AFP elevation cause | Support patient; ensure genetics/obstetric review and documented counseling plan |
| Screen-positive MoM + ultrasound suspicious for open NTD | High clinical concern pending diagnostic confirmation | Coordinate specialist appointments; avoid definitive statements; assess emotional safety |
| Screen-negative MoM | Lower estimated risk on this assay | Continue routine care; teach that screening does not exclude all defects |
| Markedly elevated MoM with twins | Expected AFP elevation in multiple gestation — different interpretation pathway | Ensure fetal number documented; obstetric review before alarming language |
Screen-Positive Anxiety and Follow-Through
| Bedside point | Nursing note |
|---|---|
| Screen ≠ diagnosis | Say “screen-positive” or “increased risk” — not “your baby has spina bifida” |
| Dating drives MoM | Confirm gestational age on every MSAFP draw; wrong dates are a common false-positive driver |
| Twins change AFP | Document multifetal pregnancy before interpreting MoM with patient |
| Negative is not absolute | Teach that screening reduces but does not eliminate risk for all NTD types |
| Follow-up tracking | Evaluate outcomes by confirming anatomy ultrasound and counseling appointments occur after screen-positive results |
| Folic acid teaching | Reinforce periconceptional folic acid for future pregnancies when clinically appropriate — not a substitute for screening |
Why Neural Tube Defect Screening is Ordered
NTD screening is offered in prenatal care to estimate fetal open neural tube defect risk. It is a population screening tool interpreted with dating, ultrasound, and specialist pathways.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Routine second-trimester open NTD risk assessment | Is estimated fetal open spina bifida or anencephaly risk increased on this assay? | Elevated maternal serum AFP MoM in the appropriate gestational window prompts targeted ultrasound and counseling per obstetric protocol. |
| Component of quadruple or integrated prenatal panel | How does AFP MoM combine with other markers on the laboratory report? | AFP as part of larger prenatal blood screening panels; nurses route full panel reports to obstetric reviewers. |
| Follow-up after uncertain dating or prior screen discordance | Should MSAFP be repeated or reinterpreted after corrected gestational age? | Incorrect dating is a common cause of false-positive MoM; prescriber and laboratory guidance determine repeat testing. |
| Evaluate outcomes after screen-positive MSAFP | Was anatomy ultrasound completed and counseling documented? | Safe screening pathways require imaging and communication after elevated MoM — not patient discharge with unresolved results. |
Contraindications and Precautions
There is no absolute contraindication to maternal venipuncture for MSAFP when ordered. Do not collect when identity or labels are uncertain, or when the order type (maternal screen versus tumor marker AFP) is unresolved.
- Counseling patients that screen-positive MoM confirms spina bifida or anencephaly before ultrasound or diagnostic testing
- Drawing MSAFP without verified gestational age in the laboratory screening window
- Screen-positive MoM without documented obstetric notification or follow-up imaging plan
- Multiple gestation, fetal demise, and maternal weight can affect MoM — document context on the chart
- Screen-negative results do not exclude all neural tube defects, including some closed defects
- MoM cutoffs and reference materials vary by laboratory — use the reporting laboratory interpretation
- Screen-positive MoM without scheduled or completed obstetric review and ultrasound plan
- Markedly discordant MoM with uncertain gestational age or twin pregnancy not documented
- Patient distress or self-harm risk after screen-positive result — activate behavioral health pathway per policy
Patient Preparation
Preparation focuses on dating verification, order clarification, emotional support, and correct serum collection — fasting is usually not required.
Pre-test checksDocument insulin-treated diabetes and antiepileptic medicines when recorded — maternal screening MoM calculations may adjust for diabetes status per laboratory protocol. Do not withhold medication unless prescriber orders — review for interpretation context only.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Neural Tube Defect Screening. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Maternal NTD screening reports AFP as MoM or screen-positive/screen-negative classification per laboratory. Interpret with gestational age, fetal number, and imaging — not in isolation.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Negative / not detected | MoM near 1.0 or screen-negative per reporting laboratory | Lower estimated risk for open NTD on this assay in current context | Continue routine prenatal care; reinforce screening limits and symptom reporting |
| Equivocal / borderline | MoM near institutional screen cutoff | May require laboratory or obstetric review depending on local policy | Confirm dating; communicate result per protocol without diagnosing fetal anomaly |
| Positive / elevated | Elevated MoM or screen-positive (cutoff varies — often ≥2.0–2.5 MoM) | Increased estimated risk for open NTD and other AFP-related conditions per report | Notify obstetric team; coordinate targeted ultrasound and genetics counseling |
| Not applicable / below detection limit | Low MoM when reported on broader prenatal panel | May relate to separate aneuploidy screening interpretation — follow full panel report | Route to obstetric genetics per laboratory obstetric interpretation |
Screen-Positive MoM and Delayed Obstetric Follow-Up
Universal laboratory critical MoM thresholds for MSAFP are Turnaround and screening rules vary by institution; follow local institutional policy. Clinical urgency often reflects screen-positive classification with missing ultrasound, unresolved dating, or acute patient safety concerns.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Screen-positive MoM without obstetric contact | Elevated MoM or screen-positive flag with no documented provider notification | Notify obstetric team per facility policy; track ultrasound and counseling appointments |
| Markedly elevated MoM with uncertain dating | Very high MoM plus gestational age conflict between LMP and ultrasound | Escalate for dating clarification before patient counseling on fetal diagnosis |
| Acute behavioral health risk after screen-positive counseling | Patient expresses self-harm thoughts or severe distress after result disclosure | Activate behavioral health and obstetric support pathways per institutional protocol |
Escalate according to facility policy when screen-positive results lack timely obstetric follow-up, dating remains uncertain, or the patient is at risk for harm related to result communication.
Factors Affecting Results
MoM interpretation depends on accurate gestational age, assay method, and maternal factors used in laboratory adjustment algorithms.
- Incorrect gestational age (common) — raises or lowers MoM erroneously
- Multiple gestation — AFP elevation may reflect twins rather than NTD
- Fetal abdominal wall defects (e.g., omphalocele) — can elevate AFP without open NTD
- Closed neural tube defects may not significantly raise MSAFP
- Sampling outside recommended gestational window
- Assuming screen-negative MoM excludes all fetal structural anomalies
- Wrong gestational age or outdated dating source
- Maternal weight, race/ethnicity, and diabetes adjustments per laboratory
- Hemolyzed or mislabeled serum specimen
MSAFP screening estimates risk and cannot diagnose neural tube defects. Confirmation requires integrated assessment including detailed ultrasound and, when indicated, diagnostic fetal testing per specialist teams.
Nursing Responsibilities
Nursing care centers on dating verification, safe specimen handling, accurate result communication, emotional support, and tracking obstetric follow-through after screen-positive MoM.
Before the TestDocumentation
Documentation should show correct screening context, MoM result, communication, and follow-up without overinterpreting screening as diagnosis.
“MSAFP drawn 0930 at 17+2 weeks (dating: early ultrasound 12+4 w). Gold-top serum; labels verified at bedside. Result: AFP 2.8 MoM (screen-positive per laboratory). Patient anxious; teaching provided that this is a screening result requiring ultrasound — not a confirmed diagnosis. Obstetric NP notified 1405; detailed anatomy ultrasound scheduled 22 Jun. Evaluate outcomes at imaging visit.”
- Gestational age, dating source, and fetal number
- Order type (maternal NTD screen / panel) and specimen details
- MoM value or screen classification with laboratory reference
- Obstetric notification, read-back, and follow-up imaging or genetics plan
- Patient teaching on screening versus diagnostic limits
- Evaluate outcomes when ultrasound and counseling are completed
Patient and Family Education
Use plain language that NTD screening estimates risk and that more tests may be needed after an abnormal result.
Neural Tube Defect Screening NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Neural Tube Defect Screening safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Maternal serum AFP (MSAFP) — neural tube defect screening
- Indication: Second-trimester open NTD risk assessment at 17 weeks gestation
- Timing: Serum collected today; dating: ultrasound confirmed 17+1 weeks
- Related orders: Detailed fetal anatomy ultrasound scheduled in 5 days; quad screen panel pending full report
- Result: AFP 2.8 MoM — screen-positive per laboratory (cutoff 2.5 MoM)
- Trend / prior value: No prior MSAFP; first prenatal screen in this pregnancy
- Pending tests: Anatomy ultrasound not yet performed; genetics counseling referral not documented
- Vital signs: Temp 36.7°C, HR 82/min, BP 118/72 mmHg, RR 16/min, SpO₂ 99% room air
- Symptoms: No bleeding or abdominal pain; reports anxiety after reading online about spina bifida
- Focused assessment: Singleton pregnancy on prior ultrasound; fundal height consistent with dates; patient tearful but coherent
- Preparation notes: Gestational age verified with clinic ultrasound record; patient told this was a screening blood test
- Collection events: Gold-top serum collected; labels correct; no hemolysis noted
- Teaching gaps / safety concerns: Patient told by friend that 2.8 MoM means the baby definitely has spina bifida; no obstetric call documented yet
Answer key & rationale
Frequently Asked Questions
FAQ
Does neural tube defect screening diagnose spina bifida?
No. MSAFP screening estimates risk using MoM. Diagnosis requires integrated assessment including detailed ultrasound and, when indicated, diagnostic fetal testing per specialist teams.
Does the patient need to fast before MSAFP?
Usually no. no special preparation for AFP blood testing unless additional instructions appear on the order or local policy.
When is second-trimester MSAFP screening typically performed?
Institutions use second-trimester maternal screening windows per laboratory and obstetric protocol — commonly approximately 15–20 weeks gestation. Confirm local guidance.
What does an elevated MoM mean?
An elevated MoM suggests increased estimated risk for open neural tube defects and other AFP-related conditions on that assay. Obstetric teams interpret the result with dating, ultrasound, and sometimes additional tests.
Can a normal MSAFP exclude all neural tube defects?
No. Screening reduces risk but does not eliminate all defects, including some that may not significantly raise MSAFP.
What nursing action follows a screen-positive MoM?
Notify the obstetric team per protocol, support accurate patient teaching, coordinate targeted ultrasound and counseling, document communication, and evaluate outcomes when follow-up is complete.
How is MSAFP different from NIPT?
MSAFP estimates open neural tube defect risk in second-trimester screening pathways. NIPT primarily screens for selected chromosomal conditions using cell-free DNA and does not replace MSAFP where open NTD screening is offered.
References
References
-
U.S. National Library of Medicine. Alpha fetoprotein. MedlinePlus Medical Encyclopedia.https://medlineplus.gov/ency/article/003573.htm
-
Mayo Clinic Laboratories. Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum. Test ID MAFP1.https://www.mayocliniclabs.com/test-catalog/Overview/113382
-
American College of Obstetricians and Gynecologists. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin.https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/07/screening-for-fetal-chromosomal-abnormalities
-
Centers for Disease Control and Prevention. Neural Tube Defects. CDC.https://www.cdc.gov/ncbddd/birthdefects/neuraltube-defects.html
-
NHS England. Fetal anomaly screening programme (FASP) handbook. GOV.UK.https://www.gov.uk/government/publications/fetal-anomaly-screening-programme-handbook
-
U.S. National Library of Medicine. Alpha-Fetoprotein (AFP) Tumor Marker Test. MedlinePlus.https://medlineplus.gov/lab-tests/alpha-fetoprotein-afp-tumor-marker-test/
-
Adigun OO, Yarrarapu SNS, Zubair M, Khetarpal S. Alpha-Fetoprotein Analysis. StatPearls. NIH Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK539816/
-
U.S. Preventive Services Task Force. Folic Acid Supplementation to Prevent Neural Tube Defects. JAMA, 2023.https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Neural Tube Defect Screening.
Policies: Medical Review Process · Editorial Policy · Correction Policy